IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
-3.03%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$705M
AUM Growth
+$705M
(-7.5%)
Cap. Flow
-$3.36M
Cap. Flow
% of AUM
-0.48%
Top 10 Holdings %
Top 10 Hldgs %
36.96%
Holding
95
New
21
Increased
24
Reduced
14
Closed
29
Top Buys
| 1 |
Tenet Healthcare
THC
|
$20.3M |
| 2 |
Amgen
AMGN
|
$17.5M |
| 3 |
Medtronic
MDT
|
$17.2M |
| 4 |
Becton Dickinson
BDX
|
$16.8M |
| 5 |
DexCom
DXCM
|
$16.3M |
Top Sells
| 1 |
Cigna
CI
|
$34.3M |
| 2 |
Zimmer Biomet
ZBH
|
$25.8M |
| 3 |
Centene
CNC
|
$13.5M |
| 4 |
AbbVie
ABBV
|
$13.5M |
| 5 |
Schrodinger
SDGR
|
$13.2M |
Sector Composition
| 1 | Healthcare | 99.61% |
| 2 | Consumer Discretionary | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
SI-BONE Inc
SIBN
$700M
| $10.3M | 1.43% |
485,000
+258,000
| +114% | +$5.48M |
|
27
Teva Pharmaceuticals
TEVA
$21.5B
| $10.2M | 1.41% |
1,000,000
| – | – |
|
28
Guardant Health
GH
$8.11B
| $9.63M | 1.33% |
325,000
-87,000
| -21% | -$2.58M |
|
29
Neurocrine Biosciences
NBIX
$13.5B
| $9.56M | 1.32% |
+85,000
| New | +$9.56M |
|
30
Zentalis Pharmaceuticals
ZNTL
$123M
| $9.03M | 1.25% |
450,000
| – | – |
|
31
Lifestance Health
LFST
$2.14B
| $8.93M | 1.24% |
1,300,000
+527,000
| +68% | +$3.62M |
|
32
Viking Therapeutics
VKTX
$3.02B
| $8.86M | 1.23% |
800,000
+70,000
| +10% | +$775K |
|
33
Natera
NTRA
$23B
| $8.85M | 1.23% |
+200,000
| New | +$8.85M |
|
34
Hologic
HOLX
$14.7B
| $8.68M | 1.2% |
125,000
-50,000
| -29% | -$3.47M |
|
35
Elanco Animal Health
ELAN
$8.62B
| $8.41M | 1.16% |
748,000
+548,000
| +274% | +$6.16M |
|
36
Krystal Biotech
KRYS
$4.35B
| $8.12M | 1.12% |
70,000
+8,000
| +13% | +$928K |
|
|
37
Zimmer Biomet
ZBH
$20.8B
| $7.86M | 1.09% |
70,000
-230,000
| -77% | -$25.8M |
|
38
Alkermes
ALKS
$4.95B
| $7.7M | 1.07% |
275,000
-9,000
| -3% | -$252K |
|
|
CTLT
39
DELISTED
CATALENT, INC.
CTLT
| $7.28M | 1.01% |
+160,000
| New | +$7.28M |
|
40
BridgeBio Pharma
BBIO
$9.91B
| $7.25M | 1% |
+275,000
| New | +$7.25M |
|
|
ITCI
41
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.93M | 0.96% |
133,000
-9,000
| -6% | -$469K |
|
42
Relay Therapeutics
RLAY
$709M
| $6.73M | 0.93% |
800,000
+100,000
| +14% | +$841K |
|
43
Pacific Biosciences
PACB
$378M
| $6.68M | 0.92% |
+800,000
| New | +$6.68M |
|
44
Supernus Pharmaceuticals
SUPN
$2.52B
| $6.07M | 0.84% |
220,000
+145,000
| +193% | +$4M |
|
45
Crinetics Pharmaceuticals
CRNX
$3.26B
| $5.95M | 0.82% |
+200,000
| New | +$5.95M |
|
|
WBA
46
DELISTED
Walgreens Boots Alliance
WBA
| $5.56M | 0.77% |
+250,000
| New | +$5.56M |
|
47
Roivant Sciences
ROIV
$8.6B
| $5.26M | 0.73% |
+450,000
| New | +$5.26M |
|
48
Merck
MRK
$210B
| $5.15M | 0.71% |
+50,000
| New | +$5.15M |
|
49
Akero Therapeutics
AKRO
$3.65B
| $5.06M | 0.7% |
100,000
+30,000
| +43% | +$1.52M |
|
50
Cabaletta Bio
CABA
$144M
| $5.02M | 0.7% |
+330,000
| New | +$5.02M |
|